I believe the gist of it is: FDA is willing to accept new potency data generated to pave the way for FDA to consider pH 3 trial MAB-GVHD001 gor paediatrics as adequate study. I think (a) a few months is quite a good time frame for a potentially significant outcome.
Re adults, a 12 month controlled single arm is also quite a reasonable outcome and given the data and evidence already, that should be a matter of ticking the box ... something FDA likes.
So, much better than we could have potentially ntcipated.
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 707 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 7320 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |